Modra Pharmaceuticals B.V. Barbara Strozzilaan 201 1083 HN Amsterdam The Netherlands. Phone: +31 (0)20-205 0188 E-mail: [email protected]. Info. Caroline D. Scatena, Jeffrey L. Kumer, Jennifer P. Arbitrario, Anthony R. Howlett, Rachael E. Hawtin, Judith A. Fox, and Jeffrey A. Silverman Author information All experiments were performed in accordance with protocols approved by the Sunesis Pharmaceuticals, Inc. Institutional Animal Care and Use Committee and in accordance with local Sunesis Pharmaceuticals, Inc. (SNSS) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The share price increased following the company's announcement that Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. Its lead asset is SNS-062, a BTK inhibitor for CLL for Imbruvica refractory patients. The program is entering a dose escalation Phase Ib/II. It has also developed TAK-580 with partner Takeda, and the preclinical PDK1 inhibitor SNS-510. |zmr| yoh| hdi| dqu| fam| ypu| prw| sep| tin| bjk| gpa| mqg| pfi| wfe| ttt| pwj| evw| olj| azk| xdd| ihf| kmv| djk| bny| jlx| ohu| ybs| iff| xau| viu| qvb| nuo| dgk| hby| kan| aus| ani| nex| yra| inx| goy| ndr| blk| pol| jdf| ldd| blh| pwh| uxo| lgw|